TY - JOUR
T1 - The stress response protein REDD1 as a causal factor for oxidative stress in diabetic retinopathy
AU - Miller, William P.
AU - Sunilkumar, Siddharth
AU - Dennis, Michael D.
N1 - Funding Information:
This research was supported by the American Diabetes Association Pathway to Stop Diabetes Grant 1-14-INI-04, National Institutes of Health grants R01 EY029702 (to MDD), and F31 EY031199 (to WPM). The authors thank Alistair Barber and Scot Kimball (Penn State College of Medicine) for critically evaluating the manuscript.
Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2021/3
Y1 - 2021/3
N2 - Diabetic Retinopathy (DR) is a major cause of visual dysfunction, yet much remains unknown regarding the specific molecular events that contribute to diabetes-induced retinal pathophysiology. Herein, we review the impact of oxidative stress on DR, and explore evidence that supports a key role for the stress response protein regulated in development and DNA damage (REDD1) in the development of diabetes-induced oxidative stress and functional defects in vision. It is well established that REDD1 mediates the cellular response to a number of diverse stressors through repression of the central metabolic regulator known as mechanistic target of rapamycin complex 1 (mTORC1). A growing body of evidence also supports that REDD1 acts independent of mTORC1 to promote oxidative stress by both enhancing the production of reactive oxygen species and suppressing the antioxidant response. Collectively, there is strong preclinical data to support a key role for REDD1 in the development and progression of retinal complications caused by diabetes. Furthermore, early proof-of-concept clinical trials have found a degree of success in combating ischemic retinal disease through intravitreal delivery of an siRNA targeting the REDD1 mRNA. Overall, REDD1-associated signaling represents an intriguing target for novel clinical therapies that go beyond addressing the symptoms of diabetes by targeting the underlying molecular mechanisms that contribute to DR.
AB - Diabetic Retinopathy (DR) is a major cause of visual dysfunction, yet much remains unknown regarding the specific molecular events that contribute to diabetes-induced retinal pathophysiology. Herein, we review the impact of oxidative stress on DR, and explore evidence that supports a key role for the stress response protein regulated in development and DNA damage (REDD1) in the development of diabetes-induced oxidative stress and functional defects in vision. It is well established that REDD1 mediates the cellular response to a number of diverse stressors through repression of the central metabolic regulator known as mechanistic target of rapamycin complex 1 (mTORC1). A growing body of evidence also supports that REDD1 acts independent of mTORC1 to promote oxidative stress by both enhancing the production of reactive oxygen species and suppressing the antioxidant response. Collectively, there is strong preclinical data to support a key role for REDD1 in the development and progression of retinal complications caused by diabetes. Furthermore, early proof-of-concept clinical trials have found a degree of success in combating ischemic retinal disease through intravitreal delivery of an siRNA targeting the REDD1 mRNA. Overall, REDD1-associated signaling represents an intriguing target for novel clinical therapies that go beyond addressing the symptoms of diabetes by targeting the underlying molecular mechanisms that contribute to DR.
UR - http://www.scopus.com/inward/record.url?scp=85100312118&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100312118&partnerID=8YFLogxK
U2 - 10.1016/j.freeradbiomed.2021.01.041
DO - 10.1016/j.freeradbiomed.2021.01.041
M3 - Review article
C2 - 33524531
AN - SCOPUS:85100312118
SN - 0891-5849
VL - 165
SP - 127
EP - 136
JO - Free Radical Biology and Medicine
JF - Free Radical Biology and Medicine
ER -